Category Archives: TB

IDWeek: Some progress in TB drug and diagnostic development, but not enough

By on .

The emerging crisis of multidrug-resistant tuberculosis is a “personal and health system catastrophe” that’s occurring half a million times a year in the form of new cases, Eric Nuermberger said at an IDWeek session on HIV-related opportunistic diseases. Not only is it an intensively difficult disease to treat, requiring up to two years of therapy […]

TB trials highlight needs, opportunities

By on .

Two recently announced tuberculosis study results  could change approaches to treatment delivery and development, but only if funding allows the realization of the opportunities they highlight. One of the studies was the REMoxTB trial, which set out to address the desperate need for shorter, simpler routes to cure tuberculosis, by determining if substituting the antibiotic […]

Xpert use reduced wait for treatment, study shows, but health system, patient challenges remain barriers to full benefits

By on .

The demand for, and the promise of, quick accurate tools to diagnose tuberculosis, and to discover resistance to basic TB treatments, are based on a simple and seemingly irrefutable premise. Such tools, it has been pointed out, make early and effective treatment possible, benefiting both patients and public with faster and more frequent cures, and […]

PaMZ TB drug regimen: Cheaper, simpler, safer and with effectiveness “significantly greater” than standard regimen, researchers say

By on .

An analysis of eight-week data from a clinical trial of a tuberculosis treatment regimen shows the promise of curing the disease in a shorter period of time, at a fraction of the current cost, and with no need for painful injections, researchers at the International AIDS Conference in Melbourne, Australia said Monday. They were announcing […]

Childhood tuberculosis: Study finds larger global hidden epidemic

By on .

Indications of a  “huge undiagnosed reservoir” of pediatric tuberculosis, with actual incidence much higher than the number of cases reported highlight the need for additional study of the disease in children, and an opportunity for improved prevention through household screening, a study released in The Lancet today says. Authors of the study, produced by researchers […]

Linezolid: Affordable generic access win highlights obstacles to life-saving treatment

By on .

With side effects that include stomach pain, vision problems, vomiting, diarrhea,  and anemia as well as pain, weakness, and numbness in hands and feet, linezolid is not something you would take if you had much choice. But for patients in Khayelishta, a township in South Africa’s Western Cape where rates of poverty, HIV and tuberculosis […]

Tuberculosis panel: U.S. effort must focus, prioritize, coordinate

By on .

With the resources allotted to fight tuberculosis worldwide inadequate to demands of a pandemic complicated by drug-resistant strains and the impact of HIV globally, the United States will need to better lead, coordinate, focus and prioritize its efforts, or risk seeing domestic and international goals compromised. That is among the conclusions of a summary report […]

TAG’s TB drug guide aims to equip activists

By on .

While the impact of tuberculosis grew over the last decades of the 20th century, with drug resistant forms of the disease and HIV fueling its spread and slowing cures, the drugs used to treat TB have not changed. Bedaquiline and delaminid are the only new TB drugs to have been approved in over forty years, […]

When XDR-TB spread in Mumbai, “lots of togetherness” led to a path of solutions

By on .

In Mumbai, the challenges to controlling the spread of drug-resistant TB are as dense, diverse and sprawling as the place itself. A small dot on the map, it is a “mega city,” as Mumbai TB officer Dr. Minni Khetarpal notes. It is the economic capital of India, the most urbanized region, and an epicenter for […]

TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

By on .

Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was […]